WeLeader Biomedical Co Ltd

WeLeader Biomedical has a market capitalization of TWD 3,047,093,000 and a price-to-earnings ratio of 68.89, indicating a high valuation relative to its earnings. The company's price-to-book ratio is 3.42, suggesting that the market values the company at a premium to its book value. The enterprise value to EBITDA ratio is 68.93, which is significantly higher than the industry median, indicating a high valuation relative to its earnings before interest, taxes, depreciation, and amortization. The company's profitability is reflected in its return on equity of 4.97% and return on assets of 2.43%, both of which are below the industry median, suggesting that the company is not generating returns as efficiently as its peers. The gross profit margin is 33.88%, and the operating margin is 23.04%, which are both in line with the industry median. The net profit margin is 18.82%, which is also in line with the industry median. WeLeader Biomedical's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's revenue is primarily derived from the sale of medical equipment and supplies. The company's revenue concentration in a single segment increases its exposure to market-specific risks. The company's revenue growth is expected to be modest, with a projected increase of 2.5% in the current fiscal year and 3.0% in the next fiscal year. The company's capital expenditures are negative, indicating that it is reducing its investment in fixed assets. The company's free cash flow is TWD 16,948,000, which is a small positive amount, indicating that the company is generating limited cash from its operations. The company's liquidity risk is medium, with a current ratio of 1.32, indicating that it has sufficient current assets to cover its current liabilities. The company's debt-to-equity ratio is 0.77, which is below the industry median, suggesting that it is not overly leveraged. The company's net cash position is negative after subtracting total debt, which increases its liquidity risk. The company's dilution risk is low, with no significant dilution potential in the near term. Recent events include the company's 2023 annual report, which disclosed its financial performance and strategic initiatives. The company has not issued any new shares in the past year, and there are no indications of a significant dilution event in the near future. The company's recent financial performance has been stable, with no significant changes in its business operations.